Drug recall · February 1, 2023
SEMAGLUTIDE 0.5MG/ML recall
Why: Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
SEMAGLUTIDE 0.5MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 1MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 2MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 4MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 5.4MG/ML (0.5ML VIAL) INJECTABLE, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.
- Lots / codes
t20221026@52 t20221102@11 t20221004@44 t20221116@36 t20221011@36
- Quantity
- N/A
- Company
- Pharmacy Innovations, Erie, PA
- Distribution
- Nationwide in the USA
- Initiated
- December 22, 2022 · Voluntary: Firm initiated
- Classified
- January 26, 2023
- Reported
- February 1, 2023
- Ended
- July 31, 2024
- How notified
- Telephone
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.